CONTACT-2: Cabozantinib + Atezolizumab for Patients with Metastatic Castration-Resistant Prostate Cancer

Dr. Neeraj Agarwal, professor of medicine and director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, presented the primary results of the phase III CONTACT-2 study at the ASCO GU meeting in 2024. Listen as Dr. Neeraj Agarwal explains why he is hoping to make the drug combination cabozantinib + atezolizumab available at his clinic.